

Safe Medicines Practice Committee

Wednesday 30th March 2022, 14:00 – 15:30

MS Teams

Minutes

Name	Initials	Role	Pres./Apols	Jan- Dec
		Chair - Director of Pharmacy	Yes	2/2
		Medicines Safety Officer	Yes	2/2
		Director of Pharmacy	Yes	2/2
		Clinical Audit Facilitator	Yes	2/2
		Consultant	Yes	2/2
		Senior Pharmacist	Yes	2/2
		Senior Pharmacist	Yes	2/2
		Lead Paediatric Nurse	Yes	2/2
		Senior Sister	Yes	2/2
		TCPD Pharmacy Manager	Yes	2/2
		Diabetes Specialist Nurse	Yes	1/2
		Clinical Patient Safety and Risk Manager	Yes	1/2
		Clinical Nurse Specialist	Yes	1/2
		Lead Pharmacy Technician	Apologies	1/2
		Matron	Apologies	1/2
		Matron	Apologies	1/2
		Associate Chief Nurse and Deputy Director of Quality	Apologies	0/2
		Doctor, ST in Clinical Oncology	Apologies	0/2
		Quality & Standards Matron	Apologies	0/2
		Senior Pharmacist	Apologies	0/2
		Consultant Anaesthetist	Apologies	0/2
		Paediatric Specialist Clinician	Apologies	0/2
		Advanced Specialist Pharmacist	Apologies	0/2
		Clinical Pharmacist	No	0/2
		Associate Chief Nurse	No	0/2
		Principal Radiographer	No	0/2
		Senior Sister	No	0/2
		Ward Manager	No	0/2
		Advanced Clinical Practitioner	No	0/2
			No	0/2
		Doctor, ST in Medical Oncology	No	0/2
		Deputy Ward Manager	No	0/2
		Consultant Therapeutic Radiographer	No	0/2
		Palliative Care Pharmacist	No	0/2
		Nurse Clinician	No	0/2
		Clinical Governance Lead	No	0/2
		Senior Specialist Pharmacist	No	0/2
		Clinical Research Nurse	No	0/2
		Senior Clinical Research Nurse	No	0/2
		Specialist Clinical Pharmacist	No	0/2
		PA, Minute-taker	Yes	2/2



Ref	Item
22/22	Welcome & Apologies Apologies as above. The Group agreed to monitor attendance with a view to streamlining the membership for non-attendees.
23/22	Declarations of interest No interests declared
24/22	Minutes of the Last Meeting The Committee approved the minutes of the last meeting as an accurate record.
25/22	SMPC Action Log The Committee updated the Action Log.
26/22	Matters arising The Group had no matters to note.
27/22	Rolling Programme <ul style="list-style-type: none"> The Medicines Practice Operational Policy is being reviewed The first 4 documents on the programme are being followed up on and the first are on schedule
28/22	For Approval No items
29/22	Audits <ol style="list-style-type: none"> Annual Safe Medicines Practice Audit: prescribing administration and storage 2021 (partial re-audit) – this has been delayed due to covid but is due in May, waiting on information regarding the Safety Audit day on the wards. Omitted meds This is ongoing with the reaudit of patient charts about to start OP prescribing (2952) The Group approved deferring this audit until May noting the benefits of transferring everything to e-prescribing. To be discussed further at the beginning of May (Action xxx) 3043 Audit of safe meds practice in Interventional Radiology The audit is scheduled for late April 2698 Patient Group Directions (PGDs) Audit 2021 – The Chair will discuss with XX (Action xxx, xxxx)
30/22	Reports SMPC Incident Review March 2022 All Meds Incidents Feb 2022 <ul style="list-style-type: none"> PMCH briefed the group on the changes in displaying information on the graphs The CCU ward manager has been contacted to relay any shared learning due to decreasing incidents Ward 10 identified the increased number of datixes are due to new starters and unfamiliarity with processes The possibility of using smart pumps for IVs will be investigated (Action xxxx) The increase in TPN incidents has been reported to Friday Focus xxxx noted a change in incident categorisation may have been responsible for increased number of medication incidents



Ref	Item
	SACT Medication Incidents February 2022 <ul style="list-style-type: none"> A significant reduction in reporting was noted with 41 in February rather than the expected 60-70. This may also have been affected by the change in reporting on the wards. XXXX can discuss with xxxx if it remains a concern. XXXX raised an issue of deferrals being recorded in CWP but not happening in practice. The mitigation is an IT request to link CWP with iQemo.
31/22	Updates MHRA Drug Safety Update (DSU) MHRA Drug Safety Update Review March 2022 The updates have been shared with the Pharmacists.
32/22	PGD approvals No items
33/22	PGDs with no amendments No items
34/22	PGDs with amendments No items
35/22	Retired PGDs No Items
36/22	PGDs for Review Alprostadil 2022 Dextrose 5% 2022 Lidocaine and Prilocaine cream 2022 Tamsulosin (surgery) 2022 Atropine (Irinotecan) 2022 Hydrocortisone Cream 2022 Paracetamol 2022 Tetrocaine Gel 2022 The Committee approved all PGDs above with consideration to the Paracetamol PGD being amended following the decision on dosage for adults with low body weight.
37/22	New Requests – PGDs No Items
38/22	Protocols/SOPs/Policies for Approval Clinical Guidance Nausea and Vomiting XXXXteam have developed this policy adapted from Manchester Royal Infirmary's chemotherapy guidelines due to a shortage of national guidance. The Group discussed the concerns around developing paediatric guidelines for the Proton Beam Therapy Centre against the need for a clear policy to clarify prescribing. Further discussions are required to confirm a consistent approach (Action xxxxx).



Ref	Item
	The Committee approved the Policy with the consideration the doses are consistent with MFT's policy and with a review in May for upcoming Levomepromazine drug licensing changes.
39/22	<p>Updates from sub-committees</p> <p>Non-Medical Prescribing Group No update</p> <p>Chemotherapy Delivery Group The fall in incident reporting has been previously noted</p> <p>Medicines Safety Group TOR v0.3 The Committee will be updated following the Medicines Safety Group's first meeting.</p>
40/22	<p>For Information/Noting/Discussion</p> <ol style="list-style-type: none"> 1. HSIB Paracetamol Investigation <ol style="list-style-type: none"> a) HSIB report – Unintentional Paracetamol Overdose in Adult Patients b) HSIB Summary Report - Unintentional Paracetamol Overdose in Adult Patients c) Reduced Paracetamol Reminder <p>The Group discussed Paracetamol dosing in adults with low body weight. The Chair will look at dosing proposals for IV and Oral and update at the next meeting. Any decision will need to be feedback to XXXXX for the Paracetamol PGD and be reflected in the Self-Medication and Safe Medicines policies.</p> <ol style="list-style-type: none"> 2. Eezycd – A ruler-type device for measuring the volume of controlled drug liquids <ol style="list-style-type: none"> a. Pharmaceutical journal article b. Company website <p>The Chair approved further investigation of the product and obtaining any validation available from the company to prepare for the Trust's own validation. xxxx will update the Group (Action xxxx)</p> <ol style="list-style-type: none"> 3. Regulation 28 report - nitrofurantoin <p>SMPC noted the document with no actions required.</p>
41/22	<p>Issues for escalation to Patient Safety Committee.</p> <p>No issues.</p>
42/22	<p>Any other business</p> <p>No issues.</p>
Date and time of next meeting: Wednesday 11 th May 2022, 14:00-15:30, MS Teams	

